As of 2025-12-19, the EV/EBITDA ratio of Ionis Pharmaceuticals Inc (IONS) is -39.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IONS's latest enterprise value is 13,462.21 mil USD. IONS's TTM EBITDA according to its financial statements is -344.05 mil USD. Dividing these 2 quantities gives us the above IONS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 17.8x | 11.2x |
| Forward P/E multiples | 11.1x - 17.9x | 12.2x |
| Fair Price | (29.11) - (43.34) | (30.44) |
| Upside | -137.5% - -155.8% | -139.2% |
| Date | EV/EBITDA |
| 2025-12-18 | -38.77 |
| 2025-12-17 | -38.87 |
| 2025-12-16 | -39.48 |
| 2025-12-15 | -40.13 |
| 2025-12-12 | -40.63 |
| 2025-12-11 | -39.84 |
| 2025-12-10 | -39.60 |
| 2025-12-09 | -39.71 |
| 2025-12-08 | -40.96 |
| 2025-12-05 | -41.04 |
| 2025-12-04 | -41.10 |
| 2025-12-03 | -41.11 |
| 2025-12-02 | -40.86 |
| 2025-12-01 | -41.18 |
| 2025-11-28 | -41.53 |
| 2025-11-26 | -41.52 |
| 2025-11-25 | -40.68 |
| 2025-11-24 | -39.55 |
| 2025-11-21 | -38.40 |
| 2025-11-20 | -37.01 |
| 2025-11-19 | -37.42 |
| 2025-11-18 | -37.66 |
| 2025-11-17 | -37.07 |
| 2025-11-14 | -36.27 |
| 2025-11-13 | -35.46 |
| 2025-11-12 | -36.79 |
| 2025-11-11 | -36.69 |
| 2025-11-10 | -35.32 |
| 2025-11-07 | -37.21 |
| 2025-11-06 | -37.47 |
| 2025-11-05 | -37.74 |
| 2025-11-04 | -36.89 |
| 2025-11-03 | -37.26 |
| 2025-10-31 | -37.56 |
| 2025-10-30 | -37.50 |
| 2025-10-29 | -36.42 |
| 2025-10-28 | -37.22 |
| 2025-10-27 | -36.94 |
| 2025-10-24 | -35.94 |
| 2025-10-23 | -36.24 |
| 2025-10-22 | -36.24 |
| 2025-10-21 | -36.31 |
| 2025-10-20 | -37.21 |
| 2025-10-17 | -36.99 |
| 2025-10-16 | -36.98 |
| 2025-10-15 | -36.66 |
| 2025-10-14 | -36.18 |
| 2025-10-13 | -35.81 |
| 2025-10-10 | -35.52 |
| 2025-10-09 | -35.66 |